COVID-19 spurs Q2 sales boom at Quidel

By LabPulse.com staff writers

July 31, 2020 -- Quidel announced that revenue in its second quarter (end-June 30) has skyrocketed due to sales of COVID-19 tests.

Q2 revenue increased 86% from $108.3 million in 2019 to $201.8 million with sales of its COVID-19 tests accounting for $109 million of the growth. Specifically, rapid immunoassay product revenue increased 270% in the company's second quarter to $80.6 million, primarily due to $56.3 million in revenue for Quidel's Sofia severe acute respiratory syndrome (SARS) Antigen test.

Similarly, revenue from molecular diagnostic solutions increased $51.0 million to $55.2 million due to the Lyra SARS-CoV-2 assay, which brought in $52.7 million in sales.

However, revenue from cardiometabolic immunoassay products dropped 20% to $54.2 million due to reduced hospital visits by chest pain patients stemming from the COVID-19 pandemic. Also, specialized diagnostic solutions revenue decreased 18% to $11.8 million.

Quidel's net income for the second quarter of 2020 reached $67.7 million, compared with a net income of $1.3 million for the second quarter of 2019.

The firm showed a similar pattern of an increase in sales as well as income for the six months ended June 30.

Total revenue reached $376.4 million versus $256.2 million for the same period in 2019, again driven by COVID-19 products. Net income for the six-month period shot to $107.9 million as compared with net income of $26.1 million for the same period in 2019.

Quidel updates performance data for Sofia antigen test
Quidel has updated performance data for its Sofia immunoassay test to reflect further studies it conducted as part of its emergency use authorization...
World market outlook: COVID-19 testing evolves rapidly, lessons sink in
Worldwide, COVID-19 testing volume was on target to grow 25%-30% from May to June, reports Kalorama Information analyst Justin Saeks.
Quidel builds point-of-care respiratory infection panel with BARDA cash
Quidel is developing a point-of-care diagnostic for respiratory infections using $635K in funding from the Biomedical Advanced Research and Development...
Quidel gets amended clearance for coronavirus antigen tests
Quidel has received an amended emergency use authorization from the U.S. Food and Drug Administration to run its rapid antigen diagnostic test for the...
Quidel nets EUA, CE Mark for Lyra Direct SARS-CoV-2 assay
Quidel has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) and the CE Mark for its Lyra Direct SARS-CoV-2...

Copyright © 2020 LabPulse.com

Last Updated ls 7/31/2020 4:43:25 PM



Register below for our weekly Letter from the Editor to receive the latest Clinical Lab news and insights.
Email
Subscribe Today
Do you want to be a Microbiology Insider?

When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.

Yes, Keep Me Current